TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06722755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP device
Description: Eligible participants with OSA will be started on automatically-adjusting CPAP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP device
Description: Eligible participants with OSA will be started on automatically-adjusting CPAP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPAP technical support
Description: Trained personnel will conduct mask selection and fitting, provide continual troubleshooting, and train participants on CPAP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone follow-up for adherence feedback and self-management skills
Description: The research coordinator will call participants approximately monthly to provide any needed support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myAir
Description: Study personnel will assist participants in registering for and using the myAir (ResMed) self-tracking app. This app also provides a library of how-to videos and provides email updates to participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored messages
Description: Tailored text messages will be sent to participants. Two-way texting messaging will also be available between the study team and participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Materials
Description: A binder of written educational materials will be provided to participants.
Study: NCT06049446

Intervention type: DEVICE
Intervention: Pintuition
Description: Magnetic seed localization
Study: NCT05344222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infrared LED
Description: The participants in the active photobiomodulation group will be irradiated with infrared LED at a wavelength of 850 nm perpendicular to the surface of the skin in gentle stationary contact at three extraoral points. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Similar device - Infrared ED
Description: For the participants in the sham group, a device with a similar appearance will be used that did not emit radiation. Treatment will be administered one hour prior to the surgical procedure as well as 48 hours and seven days (removal of sutures) after the first irradiation.
Study: NCT04978272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Description: Duo-Cotecxin 20mg/160mg tabs by Holley-Cotec, Beijing, China Each treatment with DP will consist of half-strength tablets given once a day for 3 consecutive days according to weight-based guidelines.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Description: Duo-Cotecxin 20mg/160mg tabs by Holley-Cotec, Beijing, China Each treatment with DP will consist of half-strength tablets given once a day for 3 consecutive days according to weight-based guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DP Placebo
Description: Placebos will be identical appearance to DP.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DP Placebo
Description: Placebos will be identical appearance to DP.
Study: NCT06102720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Oral colchicine will be initiated with a dose of 0.5 mg per day during 14 days. Acetylsalicylic acid was used as an antiplatelet agent (300 mg on days 1 and continuing with 100 mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Dual antiplatelet therapy includes ASA (300 mg on days 1 and continuing with 100 mg/day) and clopidogrel (300 mg on days 1 and continuing with 75 mg/day).
Study: NCT04531748

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toremifene
Description: Participants will be instructed to take 60mg of oral toremifene capsule daily, 30 minutes before bedtime.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral placebo will be used with the same number and appearance to the pills as the interventions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo will be used with the same number and appearance to the pills as the interventions.
Study: NCT05419297

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Buccal Film [Belbuca]
Description: buprenorphine buccal film is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Study: NCT06722755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Description: A trained sleep coach will conduct up to 5 MET sessions with participants and 2 sessions with a CPAP partner during the study time period.
Study: NCT06704672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek SmartGuide CGM Solution
Description: The Accu-Chek SmartGuide CGM solution is used for real-time continuous glucose monitoring (CGM) in the interstitial fluid. It consists of the Accu-Chek SmartGuide device and two smartphone applications (apps): the Accu-Chek SmartGuide app and the Accu-Chek SmartGuide Predict app. The Accu-Chek SmartGuide device contains a CGM sensor pre-assembled in a sensor applicator. It has connectivity to the smartphone that is running the Accu-Chek apps. The Accu-Chek SmartGuide app is the primary display of the real-time glucose values. The Accu-Chek SmartGuide Predict app is an information management tool that further visualizes and analyzes diabetes data from the Accu-Chek SmartGuide device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Accu-Chek SmartGuide Sensor and Blinded Apps
Description: The participants in the SMBG control group will wear a SmartGuide sensor with blinded SmartGuide apps intermittently, i.e., during the assessment periods. It is not possible to read out the glucose data from the blinded app, hence neither the SmartGuide app nor the SmartGuide Predict functionalities can be accessed by the participants in this group.

Intervention type: DEVICE
Group type: OTHER
Intervention: SMBG Device
Description: With the SmartGuide apps in blinded mode, participants in the SMBG control group will continue using their own SMBG device or they may use the Accu-Chek Instant meter that will be provided for calibration of the SmartGuide device.
Study: NCT06743477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supergraft
Description: This study is a prospective, single-center, single-arm clinical study, and it is planned to include 3-5 patients with Eastern Mediterranean major who have no HSCT indication and cannot undergo Eastern Mediterranean gene therapy. The diagnosis of Eastern Mediterranean major was determined by the genotype of Eastern Mediterranean and the clinical manifestations of patients, and patients who met the inclusion criteria were screened and enrolled and received super transplant therapy.
Study: NCT06745882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given on day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given on day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given on day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given on day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given on day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given on day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given on day 1 of every 21-day cycle. After cycle 4 is given every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given on day 1 of every 21-day cycle. After cycle 4 is given every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given on day 1 of every 21-day cycle. After cycle 4 is given every 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Given on days 1, 8, and 15 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Given on days 1, 8, and 15 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given on day 1 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given on day 1 of every 21-day cycle.
Study: NCT06746116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Chemotherapy phase
Description: Durvalumab (IV) with SoC (carboplatin + paclitaxel chemotherapy: patients should receive at least 4, but preferably 6 cycles) every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab + Olaparib phase
Description: durvalumab (IV) with olaparib (tablets) every four weeks until progression.
Study: NCT05951452

Intervention type: OTHER
Intervention: Blood samples for testosterone and SHBG measurements
Description: Several measurements of the testosterone concentration will be performed on serum from 10 mL of blood collected at:~* t0 corresponding to the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video

Intervention type: OTHER
Intervention: Blood samples for testosterone and SHBG measurements
Description: Several measurements of the testosterone concentration will be performed on serum from 10 mL of blood collected at:~* t0 corresponding to the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video

Intervention type: OTHER
Intervention: Saliva samples for oxytocin measurements
Description: Several measurements of the oxytocin concentration will be performed on 2 ml saliva samples:~* t0 corresponding to 20 minutes after the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video

Intervention type: OTHER
Intervention: Saliva samples for oxytocin measurements
Description: Several measurements of the oxytocin concentration will be performed on 2 ml saliva samples:~* t0 corresponding to 20 minutes after the start of the hospital appointment and before watching the video~* t1 which corresponds to 20 minutes after watching a 2 minutes empathy-inducing video
Study: NCT05419297

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urine Drug Screening
Description: Urine drug screening to include controlled prescription medication as well as illicit substances to monitor compliance

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Urine Drug Screening
Description: Urine drug screening to include controlled prescription medication as well as illicit substances to monitor compliance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: actigraph
Description: Subjects will wear this device to monitor sleep and activity

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: actigraph
Description: Subjects will wear this device to monitor sleep and activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROMIS 29
Description: questionnaire will be administered once a week via e-dairy to monitor mood and sleep

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PROMIS 29
Description: questionnaire will be administered once a week via e-dairy to monitor mood and sleep

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sit to stand test
Description: Subjects will complete this daily with specific instructions through the e-diary
Study: NCT06664788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETHIZIA
Description: ETHIZIA patch will be applied to bleeding site intraoperatively.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL Original
Description: SURGICEL Original will be applied to bleeding site intraoperatively.
Study: NCT05419297

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sit to stand test
Description: Subjects will complete this daily with specific instructions through the e-diary

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: numerical rating scale pain score
Description: subjects will be asked a pain score in the morning, prior to, and after sit-to-stand testing, and at night

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: numerical rating scale pain score
Description: subjects will be asked a pain score in the morning, prior to, and after sit-to-stand testing, and at night

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient global impression of function
Description: subjects will be asked three questions once a day to assess their personal impression of functional status

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: patient global impression of function
Description: subjects will be asked three questions once a day to assess their personal impression of functional status

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PROMIS - sleep
Description: Subjects will answer 5 questions about sleep every morning via e-diary

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: PROMIS - sleep
Description: Subjects will answer 5 questions about sleep every morning via e-diary
Study: NCT06754826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-generated questions and feedback as a spaced repetition
Description: Participants in the intervention group will undergo structured learning sessions consisted of AI-generated questions and feedback as a spaced repetition.
Study: NCT06756984

Intervention type: PROCEDURE
Intervention: Partial Cyst Wall Resection with Nerve Root Sleeve Plasty
Description: Surgical technique involving partial removal of the cyst wall to decompress the nerve root, followed by plasty of the nerve root sleeve to restore nerve function and prevent recurrence.

Intervention type: PROCEDURE
Intervention: Partial Cyst Wall Resection with Nerve Root Sleeve Reinforcement and Reconstruction:
Description: Advanced surgical technique combining partial cyst wall removal with additional reinforcement and reconstruction of the nerve root sleeve to provide enhanced support and reduce the risk of cyst recurrence.

Intervention type: PROCEDURE
Intervention: Autologous Fat/Muscle with Fibrin Glue Microscopic Cyst Filling
Description: Minimally invasive surgical technique where autologous fat or muscle tissue is used to fill the cyst cavity, and fibrin glue is applied to seal the defect, aiming to obliterate the cyst and prevent cerebrospinal fluid leakage.
Study: NCT06754098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxecitine and Doxribtimine
Description: A combination of doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart .Dose will be increased if the tolerability profile is good.
Study: NCT06767163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iBalance
Description: Participants will engage in the device test, clinical assessment tests. The whole test will last twelve months, and the outcome will be assessed pre- and post-implementation for comparison and validation.~The intervention results are used to compared with traditional tests and clinical diagnosis, to identify whether the sensor provides a higher accuracy in predicting fall risk, and to explore the feasibility of the sensor in clinical scenarios.
Study: NCT06768931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biolosion (oral probiotic compound preparation)
Description: Biolosion (oral probiotic compound preparation) will be administered in the experimental arm. Biolosion will be taken every night from day 1 to day 21 after each cycle of immunotherapy-chemotherapy.
Study: NCT06767514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ivonescimab Injection
Description: Subject will receive ivonescimab as an IV injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab Injection
Description: Subject will receive Pembrolizumab as an IV injection
Study: NCT06767904

Intervention type: DEVICE
Group type: OTHER
Intervention: Continous Oxygen by Bottles
Description: Oxygen delivery by bottles giving a continous flow.

Intervention type: DEVICE
Group type: OTHER
Intervention: Demand oxygen by Portable Concentrator
Description: Oxygen delivery by consentrators, giving oxygen only when inhaling.
Study: NCT06752486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Giving post photorefractive keratectomy for pain relief
Description: We plan to conduct a randomized prospective study to assess the efficacy and safety of oral Gabapentin versus oral Diclofenac Potassium for postoperative analgesia in adults undergoing surface ablation. The first group will be given gabapentin orally in a dose of 300mg Tid for 72 hours and the second group will be given oral diclofenac potassium 50mg Tid for 72 hours. The drugs will be administered starting from the first day postoperative.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Giving post photorefractive keratectomy for pain relief
Description: We plan to conduct a randomized prospective study to assess the efficacy and safety of oral Gabapentin versus oral Diclofenac Potassium for postoperative analgesia in adults undergoing surface ablation. The first group will be given gabapentin orally in a dose of 300mg Tid for 72 hours and the second group will be given oral diclofenac potassium 50mg Tid for 72 hours. The drugs will be administered starting from the first day postoperative.
Study: NCT06769724

Intervention type: PROCEDURE
Intervention: Anterior cruciate ligament reconstruction surgery
Description: Anterior cruciate ligament reconstruction surgery with semitendinosus tendon autograft

Intervention type: PROCEDURE
Intervention: Anterior cruciate ligament reconstruction surgery
Description: Anterior cruciate ligament reconstruction surgery with peroneus longus autograft
Study: NCT06769711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical procedure using Peroneus Longus for ACL reconstruction.
Description: Surgical procedure using Peroneus Longus for ACL reconstruction.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical procedure using Hamstring tendons for ACL reconstruction.
Description: Surgical procedure using Hamstring tendons for ACL reconstruction.
Study: NCT06769880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound and Educational Intervention
Description: This will include the educational intervention combined with a point-of-care ultrasound

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Educational Intervention Alone
Description: This will include only the educational intervention (without ultrasound)
Study: NCT06777199

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microscopic Selective Dorsal Neurectomy (SDN)
Description: Selective dorsal neurectomy (SDN) involves microsurgical dissection and partial transection of the dorsal penile nerves to reduce glans sensitivity.~The procedure is performed under spinal anesthesia or local anesthesia with 1% lidocaine.~A midline or dorsal sub-coronal incision is made 1 cm proximal to the coronal sulcus.~The skin is retracted, exposing the Dartos fascia and Buck's fascia to reach the neurovascular bundle (two dorsal penile nerves lateral to two dorsal penile arteries).~Every other nerve on either side of the corpora cavernosa is transected to damage approximately 50% of the nerve supply to the glans.~Suturing is done using 7-0 or 8-0 prolene sutures, and the incision is closed. Patients are evaluated at 1 month and 3 months post-procedure for IELT, AIPE, and PEDT scores to determine success.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency (PRF) Nerve Ablation
Description: Pulsed radiofrequency (PRF) nerve ablation aims to reduce sensitivity of the dorsal penile nerves using low-energy radiofrequency pulses.~Under sterile conditions, a 22-gauge RF cannula (5-cm-long, 10-mm active tip) is inserted into the flaccid penile skin at the 1-o'clock position for the right dorsal penile nerve.~Sensory stimulation testing is performed at 50 Hz to identify the point of maximum glans sensitivity.~Pulsed radiofrequency is applied at an energy output of 45 V for 180 seconds at 42°C (using the NeuroTherm generator).~The procedure is repeated at the 11-o'clock position for the left dorsal penile nerve, ensuring both sides are treated.~The goal is to ablate sensation over as large an area of the glans as possible without causing permanent nerve damage.~Post-procedure, patients are evaluated at 1 and 3 months for IELT, AIPE, and PEDT scores.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraglanular Hyaluronic Acid (HA) Injection
Description: Intraglanular hyaluronic acid (HA) injection involves administering HA gel into the glans penis to reduce its sensitivity.~The circumference of the glans penis is divided into three circles (1 cm apart, starting from the base), and each circle is further divided into quarter circles.~Topical anesthetic cream (Emla®, lidocaine 25 mg + prilocaine 25 mg) is applied for 30 minutes to numb the glans.~Using two prefilled syringes of HA gel (Hyabell Ultra® 24 mg/ml with 0.3% lidocaine), 12 injections are administered into the deep dermis of the glans using a 27-G needle.~Each injection site receives 0.25 ml of HA gel following the multiple puncture technique.~Patients are evaluated at 1 and 3 months for IELT, AIPE, and PEDT scores to assess efficacy.
Study: NCT06781879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin c
Description: Chemoablation